ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 343

Low Rates of Immunizations in Cohort of Immunocompromised Patients in an Academic Rheumatology Practice

Dmitriy Cherny1, Najia Shakoor2, Todd Beck3 and Sonali Khandelwal4, 1Internal Medicine, Rush University Medical Center, Chicago, IL, 2Division of Rheumatology, Rush University Medical Center, Chicago, IL, 3Bioinformatics, Rush University Medical Center, Chicago, IL, 4Rheumatology, Rush University Medical Center, Chicago, IL

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: immunosuppressants, Infection, population studies and vaccines

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Measures and Measurement of Healthcare Quality Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Patients with rheumatologic disorders often require immunosuppression (e.g. DMARDs, biologics, or high doses of prednisone). These patients are at increased risk for infections. While live vaccines are contraindicated in the immunosuppressed, 2018 CDC guidelines support inactivated vaccine administration [1]. Despite recommendations for immunization [2], there is lack of evidence on whether vaccination rates are optimal. The purpose of this study was to investigate the rates of influenza, pneumococcal, and tetanus/diphtheria/pertussis (Tdap) vaccination in immunosuppressed individuals with rheumatologic disorders seen from 2012-2017 at a large academic rheumatology clinic.

Methods:

Patients seen at a large urban academic medical center’s rheumatology clinic between 2012-2017 were included if they had a diagnosis of rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), or vasculitis in addition to any of the following: prednisone ≥20mg/day, a DMARD (except hydroxychloroquine), and/or a biologic agent. Deceased patients were excluded. Immunizations, medications, and comorbidities were recorded. Vaccination administration for Prevnar, Pneumovax, Influenza, or Tdap was assessed. Chi squared tests evaluated immunization patterns based on various factors including sex, comorbidities, physician experience level (< 10 years, ≥ 10 years), diagnosis, and age group (< 65 years, ≥ 65 years).

Results:

Of 2366 patients reviewed, 1239 met inclusion/exclusion criteria. Results are shown in the Table. Vaccination rates were below 50% (except for receipt of flu vaccine once during the study period). More patients aged ≥ 65 years received Prevnar/Pneumovax than those <65 years of age. Patients with SLE had higher rates of immunization versus those with RA or vasculitis. Presence of cardiopulmonary comorbidities generally increased rates. No significant difference was found in rates based on ethnicity, sex, non-cardiopulmonary comorbidities, or physician experience.

Conclusion:

Infections contribute to morbidity and mortality for immunosuppressed patients, and guidelines recommend vaccination. The above results show strikingly low vaccination rates in this vulnerable population. Other risk factors for infection, including older age and cardiopulmonary comorbidities, were associated with higher vaccination rates. Rheumatologists may not be considering vaccination during their busy clinical practice. Education and quality improvement initiatives are needed to improve vaccination rates in Rheumatology clinics.

REFERENCE

  1. CDC- Immunization schedules. https://www.cdc.gov/vaccines/schedules/hcp/adult.html. May 31, 2018
  2. Van Assen S, Agmon-Levin N, Elkayam O, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2011;70:414e22.

Table 1. Vaccination rates in immunocompromised patients

Prevnar

Pneumovax

Td/Tdap

Flu (Ever)

Flu

(Past Year, 2017)

Total [n (%)]

268 (22%)

558 (45%)

320 (26%)

747 (60%)

468 (38%)

Age [n (%)]

≤ 65 years

144 (16%)

358 (40%)

230 (26%)

523 (59%)

326 (37%)

> 65 years

124 (35%)

200 (57%)

90 (26%)

224 (64%)

142 (41%)

p-value

<0.01*

<0.01*

0.95

0.09

0.20

Diagnosis [n (%)]

SLE

98 (25%)

187 (47%)

120 (30%)

246 (62%)

165 (42%)

RA

149 (20%)

314 (43%)

182 (25%)

431 (59%)

269 (37%)

Vasculitis

21 (18%)

57 (50%)

18 (16%)

70 (61%)

34 (30%)

p-value

0.15

0.21

<0.01*

0.54

0.04*

Cardiac co-morbidity [n (%)]

Yes

16 (33%)

35 (73%)

17 (35%)

36 (75%)

26 (54%)

No

252 (21%)

523 (44%)

303 (25%)

711 (60%)

442 (37%)

p-value

0.04*

<0.01*

0.12

0.03*

0.02*

Pulmonary co-morbidity [n (%)]

Yes

29 (44%)

47 (71%)

27 (41%)

52 (79%)

34 (52%)

No

239 (20%)

511 (44%)

293 (25%)

695 (59%)

434 (37%)

p-value

<0.01*

<0.01*

<0.01*

<0.01*

0.02*

* Significant result

SLE = Systemic lupus erythematosus , RA = Rheumatoid arthritis


Disclosure: D. Cherny, None; N. Shakoor, Dr. Comfort/DJO, 7; T. Beck, None; S. Khandelwal, None.

To cite this abstract in AMA style:

Cherny D, Shakoor N, Beck T, Khandelwal S. Low Rates of Immunizations in Cohort of Immunocompromised Patients in an Academic Rheumatology Practice [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/low-rates-of-immunizations-in-cohort-of-immunocompromised-patients-in-an-academic-rheumatology-practice/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/low-rates-of-immunizations-in-cohort-of-immunocompromised-patients-in-an-academic-rheumatology-practice/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology